Cited by 6,470Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Open access

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators·2001·New England Journal of Medicine

DOI 10.1056/nejmoa010746

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients. METHODS: We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months. RESULTS: The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stroke--occurred in 9.3 percent of the patients in the clopidogrel group and 11.4 percent of the patients in the placebo group (relative risk with clopidogrel as compared with placebo, 0.80; 95 percent confidence interval, 0.72 to 0.90; P<0.001). The second primary outcome--the first primary outcome or refractory ischemia--occurred in 16.5 percent of the patients in the clopidogrel group and 18.8 percent of the patients in the placebo group (relative risk, 0.86; 95 percent confidence interval, 0.79 to 0.94; P<0.001). The percentages of patients with in-hospital refractory or severe ischemia, heart failure, and revascularization procedures were also significantly lower with clopidogrel. There were significantly more patients with major bleeding in the clopidogrel group than in the placebo group (3.7 percent vs. 2.7 percent; relative risk, 1.38; P=0.001), but there were not significantly more patients with episodes of life-threatening bleeding (2.2 percent [corrected] vs. 1.8 percent; P=0.13) or hemorrhagic strokes (0.1 percent vs. 0.1 percent). CONCLUSIONS: The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa010746

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Self-citation
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
The GUSTO-I Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390704 · Cited by 1,431
Self-citation
Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382102 · Cited by 1,330
Self-citation
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
Rao, A. K., Pratt, C. M., Berke, A. D., Jaffe, A. S., Ockene, I. S., SCHREIBER, T. L., Bell, W. R., Knatterud, G. L., ROBERTSON, T. L., & Terrin, M. L. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90158-1 · Cited by 979
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial
Simoons, M. L. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05060-1 · Cited by 698
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 683
Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
Wallentin, L. C., Swahn, E., Kontny, F. P., Husted, S., Lagerqvist, B., Ståhle, E., Jd, N., Dellborg, M., Geiran, O. R., Grande, P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07350-x · Cited by 405
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
Chew, D. P., Bhatt, D. L., Sapp, S. K., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.2.201 · Cited by 359

Flagged first, then by citations

Show all 16 references

Sorted by citations

Items 301–400 of 1,007

Platelet Function Testing in Cardiovascular Diseases
Michelson, A. D. (2004) · Circulation · doi:10.1161/01.cir.0000147228.29325.f9 · Cited by 317
Guideline for investigation and management of adults and children presenting with a thrombocytosis
Harrison, C. N., Bareford, D., Butt, N. M., Campbell, P. J., Conneally, E., Drummond, M. W., Erber, W. N., Everington, T., Green, A. R., Hall, G. W., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08122.x · Cited by 317
National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016
Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.06.789 · Cited by 326
Epidemiology, classification, and modifiable risk factors of peripheral arterial disease
Shammas, N. W. (2007) · Vascular Health and Risk Management · doi:10.2147/vhrm.2007.3.2.229 · Cited by 315
Guideline on antiplatelet and anticoagulation management in cardiac surgery
Dunning, J., Versteegh, M. I. M., Fabbri, A., Pavie, A., Kolh, P. H., Lockowandt, U., & Nashef, S. A. M. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.02.024 · Cited by 318
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
The Platelet in Diabetes
Colwell, J. A., & Nesto, R. W. (2003) · Diabetes Care · doi:10.2337/diacare.26.7.2181 · Cited by 311
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
Perk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 319
Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment
Angiolillo, D. J., Bernardo, E., Ramírez, C., Costa, M. A., Sabaté, M., Jiménez‐Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.038 · Cited by 310
Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity?
Tsiara, S., Elisaf, M., Jagroop, I. A., & Mikhailidis, D. P. (2003) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960300900301 · Cited by 310
Aspirin and clopidogrel resistance: an emerging clinical entity
Wang, T. H., Bhatt, D. L., & Topol, E. J. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi684 · Cited by 308
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article
Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., Whitlow, P. L., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.025 · Cited by 307
Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1
VILESGONZALEZ, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.03.011 · Cited by 305
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J. K. E., Cuisset, T., Kirchhof, P. F., Marín, F. R., & Lip, G. Y. H. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-08-0580 · Cited by 304
Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes
Yusuf, S., Mehta, S. R., Zhao, F., Gersh, B. J., Commerford, P., Blumenthal, M., Budaj, A., Wittlinger, T., & Fox, K. A. A. (2003) · Circulation · doi:10.1161/01.cir.0000051362.96946.15 · Cited by 299
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. J., Galli, M., Collet, J., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 318
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A. L., Ziada, K. M., Berman, G. O., Strony, J. T., Joseph, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60230-0 · Cited by 297
2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T. K., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 294
Differences in the Management and Prognosis of Women and Men Who Suffer From Acute Coronary Syndromes
Anand, S. S., Xie, C. C., Mehta, S. R., Franzosi, M. G., Joyner, C. D., Chrolavicius, S., Fox, K. A. A., & Yusuf, S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.091 · Cited by 290
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter
Cairns, J. A., Connolly, S. J., McMurtry, S., Stephenson, M., & Talajic, M. R. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.11.007 · Cited by 285
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients
Andreotti, F., Testa, L., Biondi‐Zoccai, G., & Crea, F. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi485 · Cited by 288
Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Gaspoz, J., Coxson, P. G., Goldman, P. A., Williams, L. W., Kuntz, K. M., Hunink, M. G. M., & Goldman, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200206063462309 · Cited by 288
Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 297
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting
Karjalainen, P. P., Porela, P., Ylitalo, A., Vikman, S., Nyman, K., Vaittinen, M.-A., Airaksinen, T. J., Niemelä, M., Vahlberg, T. J., & Airaksinen, J. K. E. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl488 · Cited by 286
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 299
Current and future antiplatelet therapies: emphasis on preserving haemostasis
McFadyen, J. D., Schaff, M., & Peter, K. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.206 · Cited by 291
Task force on the management of chest pain
Erhardt, L. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3194 · Cited by 283
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 282
Bleeding risk assessment and management in atrial fibrillation patients
Fauchier, L., Hylek, E. M., Knight, E., Lane, D. A., Levi, M. M., Marín, F. R., Palareti, G., Jp, C., Rubboli, A., Poli, D., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0690 · Cited by 283
Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome – Randomized, Double-Blind, Phase III PHILO Study –
Goto, S., Huang, C., Park, S., Emanuelsson, H., & Kimura, T. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0112 · Cited by 279
Dexmedetomidine as a Total Intravenous Anesthetic Agent
Ramsay, M. A. E., & Luterman, D. L. (2004) · Anesthesiology · doi:10.1097/00000542-200409000-00028 · Cited by 278
Basic Principles of Platelet Biology and Clinical Implications
Angiolillo, D. J., Ueno, M., & Goto, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0982 · Cited by 279
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Rao, S. V., Eikelboom, J. W., Granger, C. B., Harrington, R. A., Califf, R. M., & Bassand, J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm019 · Cited by 273
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
Platelet Function Measurement–Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery
Mahla, E., Suarez, T., Bliden, K. P., Rehak, P., Metzler, H., Sequeira, A. J., Cho, P., Sell, J., Fan, J., Antonino, M. J., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.967208 · Cited by 269
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease
Charytan, D., & Kuntz, R. E. (2006) · Kidney International · doi:10.1038/sj.ki.5001934 · Cited by 271
Introduction: P2 Receptors
Burnstock, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043451014 · Cited by 269
Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction
Lamas, G. A., Goertz, C., Boineau, R., Mark, D. B., Rozema, T. C., Nahin, R. L., Lindblad, L., Lewis, E. F., Drisko, J., Lee, K. L., et al. (2013) · JAMA · doi:10.1001/jama.2013.2107 · Cited by 269
Trial and Error
Kaul, S., & Diamond, G. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.065 · Cited by 270
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 263
Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use
Charlot, M. G., Ahlehoff, O., Norgaard, M. L., Jørgensen, C. H., Sørensen, R., Abildstrøm, S. Z., Hansen, P. R., Madsen, J. K., Køber, L., Torp-Pedersen, C., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00005 · Cited by 264
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Teng, R., Oliver, S. D., Hayes, M. A., & Butler, K. A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032250 · Cited by 269
The Role of Aspirin in Cardiovascular Prevention
Gasparyan, A. Y., Watson, T., & Lip, G. Y. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.080 · Cited by 266
Effect of Routine Clopidogrel Use on Bleeding Complications After Transbronchial Biopsy in Humans
Ernst, A., Eberhardt, R., Wahidi, M. M., Becker, H. D., & Herth, F. J. F. (2006) · CHEST Journal · doi:10.1378/chest.129.3.734 · Cited by 261
New Antithrombotic Drugs
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · CHEST Journal · doi:10.1378/chest.08-0673 · Cited by 261
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
Goto, S., Bhatt, D. L., Röther, J., Alberts, M. J., Hill, M. D., Ikeda, Y., Uchiyama, S., D’Agostino, R. B., Ohman, E. M., Liau, C., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.029 · Cited by 261
Application of the TIMI Risk Score for Unstable Angina and Non‐ST Elevation Acute Coronary Syndrome to an Unselected Emergency Department Chest Pain Population
Pollack, C. V., Sites, F. D., Shofer, F. S., Sease, K. L., & Hollander, J. E. (2005) · Academic Emergency Medicine · doi:10.1197/j.aem.2005.06.031 · Cited by 256
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B. R., Lamm, D. L., O’Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 255
Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile
Jakubowski, J. A., Winters, K. J., Naganuma, H., & Wallentin, L. C. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00027.x · Cited by 251
The Primary and Secondary Prevention of Coronary Artery Disease
Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M. D., O’Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., & Harrington, R. A. (2008) · CHEST Journal · doi:10.1378/chest.08-0685 · Cited by 250
Part 10: Acute Coronary Syndromes
O’Connor, R. E., Brady, W. J., Brooks, S. C., Diercks, D., Egan, J. R., Ghaemmaghami, C. A., Menon, V., O’Neil, B. J., Travers, A. H., & Yannopoulos, D. (2010) · Circulation · doi:10.1161/circulationaha.110.971028 · Cited by 255
Platelet thrombin receptor antagonism and atherothrombosis
Angiolillo, D. J., Capodanno, D., & Goto, S. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp504 · Cited by 250
Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography Society of Nuclear Cardiology, Heart Rhythm Society, Society of Collaboration With the American Society of Echocardiography, American Cardiovascular Evaluation for Noncardiac Surgery): Developed in (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiology/American Heart Association Task Force on Practice Guidelines Care for Noncardiac Surgery: A Report of the American College of ACC/AHA 2007 Guidelines …
Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Buller, E., Creager, M. A., Ettinger, S. M., Faxon, D. P., Jacobs, A. K., Adams, C. D., et al. (2007) · Cited by 250
Association of Blood Transfusion With Increased Mortality in Myocardial Infarction
Chatterjee, S., Wetterslev, J., Sharma, A., Lichstein, E., & Mukherjee, D. (2012) · JAMA Internal Medicine · doi:10.1001/2013.jamainternmed.1001 · Cited by 249
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.015 · Cited by 251
Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006
Peterson, E. D., Shah, B. R., Parsons, L. S., Pollack, C. V., French, W. J., Canto, J. G., Gibson, C. M., & Rogers, W. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.028 · Cited by 248
Does Clopidogrel Increase Blood Loss Following Coronary Artery Bypass Surgery?
Chu, M. W. A., Wilson, S. R., Novick, R. J., Stitt, L., & Quantz, M. (2004) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2004.03.028 · Cited by 247
Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease
Toyoda, Ḱ., Yasaka, M., Iwade, K., Nagata, K., Koretsune, Y., Sakamoto, T., Uchiyama, S., Gotoh, J., Nagao, T., Yamamoto, M., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.504993 · Cited by 246
Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1
Armstrong, D., Summers, C., Ewart, L. C., Nylander, S., Sidaway, J. E., & van Giezen, J. J. J. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413511693 · Cited by 245
Priority medicines for Europe and the world
Kaplan, W. A., Laing, R. O., & Neal, B. C. (2004) · Cited by 244
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
Valgimigli, M., Gragnano, F., Branca, M., Franzone, A., Baber, U., Jang, Y., Kimura, T., Hahn, J., Zhao, Q., Windecker, S., et al. (2021) · BMJ · doi:10.1136/bmj.n1332 · Cited by 243
Non-adherence to cardiovascular medications
Kolandaivelu, K., Leiden, B. B., O’Gara, P. T., & Bhatt, D. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu364 · Cited by 249
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting
Zhao, Q., Zhu, Y., Xu, Z., Cheng, Z., Mei, J., Chen, X., & Wang, X. (2018) · JAMA · doi:10.1001/jama.2018.3197 · Cited by 241
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
Andreotti, F., Rocca, B., Husted, S., Ajjan, R., ten Berg, J. M., Cattaneo, M., Collet, J., Caterina, R. D., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 239
Pharmacokinetics of clopidogrel after administration of a high loading dose
Kastrati, A., Harlfinger, S., Gorchakova, O., Lazar, A., von Beckerath, N., Schömig, A., Schömig, E., & Taubert, D. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0105 · Cited by 240
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.010 · Cited by 240
Antiplatelet agents for the treatment and prevention of atherothrombosis
Patrono, C., Andreotti, F., Arnesen, H., Badimón, L., Baigent, C., Collet, J., Caterina, R. D., Gulba, D. C., Huber, K., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr373 · Cited by 239
From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Springthorpe, B., Bailey, A., Barton, P., Birkinshaw, T. N., Bonnert, R. V., Brown, R. C., Chapman, D., Dixon, J., Guile, S. D., Humphries, R. G., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.057 · Cited by 239
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
pre-diabetes Task Force on diabetes (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 239
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Schulz, S., Schuster, T., Mehilli, J., Byrne, R. A., Ellert, J., Maßberg, S., Goedel, J., Bruskina, O., Ulm, K., Schömig, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp275 · Cited by 234
Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis
Kaufman, J. S., O’Connor, T., Zhang, J. H., Cronin, R. E., Fiore, L. D., Ganz, M. B., Goldfarb, D. S., & Peduzzi, P. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000081661.10246.33 · Cited by 234
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Kuliczkowski, W., Witkowski, A., Poloński, L., Watała, C. W., Filipiak, K. J., Budaj, A., Golański, J., Sitkiewicz, D., Pręgowski, J., Górski, J., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn562 · Cited by 234
STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
Tibi, P. R., McClure, R. S., Huang, J., Baker, R. A., Fitzgerald, D., Mazer, C. D., Stone, M. E., Chu, D., Stammers, A. H., Dickinson, T., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.03.033 · Cited by 247
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale
Stone, G. W., Bertrand, M. E., Colombo, A., Dangas, G., Farkouh, M. E., Feit, F., Lansky, A. J., Lincoff, A. M., Mehran, R., Moses, J. W., et al. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.036 · Cited by 232
Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid
Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K., Easton, J. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.768283 · Cited by 233
Clopidogrel–Drug Interactions
Bates, E., Lau, W. C., & Angiolillo, D. J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.024 · Cited by 231
Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease
Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.895342 · Cited by 231
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes
Husted, S., James, S. K., Becker, R. C., Horrow, J. C., Katus, H. A., Storey, R. F., Cannon, C. P., Heras, M., Lópes, R. D., Morais, J., et al. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964395 · Cited by 231
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Giusti, B., Gori, A. M., Marcucci, R., Saracini, C., Sestini, I., Paniccia, R., Valente, S., Antoniucci, D., Abbate, R., & Gensini, G. F. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f1b2be · Cited by 230
Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control
Chang, X., Lochner, A., Wang, H.-H., Wang, S., Zhu, H., Ren, J. T., & Zhou, H. (2021) · Theranostics · doi:10.7150/thno.60143 · Cited by 231
ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).
Eagle, K. A., Guyton, R. A., Davidoff, R., Edwards, F. H., Ewy, G., Gardner, T., Hart, J. C., Herrmann, H. C., Hillis, L., Hutter, A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.021 · Cited by 83
Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients
Shireman, T. I., Howard, P. A., Kresowik, T. F., & Ellerbeck, E. F. (2004) · Stroke · doi:10.1161/01.str.0000141933.75462.c2 · Cited by 229
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Lip, G. Y. H., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J. K. E., Cuisset, T., Kirchhof, P. F., & Marín, F. R. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq117 · Cited by 229
Antithrombotic Therapy During Percutaneous Coronary Intervention
Popma, J. J., Berger, P. B., Ohman, E. M., Harrington, R. A., Grines, C. L., & Weitz, J. I. (2004) · CHEST Journal · doi:10.1378/chest.126.3_suppl.576s · Cited by 229
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups
Budaj, A., Yusuf, S., Mehta, S. R., Fox, K. A. A., Tognoni, G., Zhao, F., Chrolavicius, S., Hunt, D., Keltai, M., & Franzosi, M. G. (2002) · Circulation · doi:10.1161/01.cir.0000029926.71825.e2 · Cited by 228
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Circulation · doi:10.1161/cir.0000000000000405 · Cited by 229
Shear-Dependent Platelet Aggregation: Mechanisms and Therapeutic Opportunities
Rana, A., Westein, E., Niego, B., & Hagemeyer, C. E. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00141 · Cited by 250
Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study
Hansson, E. C., Jidéus, L., Åberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., Ivert, T., Nozohoor, S., Barbu, M., Svedjeholm, R., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv381 · Cited by 230
Late Coronary Stent Thrombosis
Windecker, S., & Meier, B. (2007) · Circulation · doi:10.1161/circulationaha.106.683995 · Cited by 226
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
Geisler, T., Graß, D., Bigalke, B., Stellos, K., Drosch, T., Dietz, K., Herdeg, C., & Gawaz, M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02812.x · Cited by 225
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study
Malinin, A. I., Pokov, A. N., Spergling, M., DeFranco, A. C., Schwartz, K. A., Schwartz, D. E., Mahmud, E., Atar, D., & Serebruany, V. L. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.01.019 · Cited by 225
Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting
Kulik, A., May, M. R. L., Voisine, P., Tardif, J., DeLarochellière, R., Naidoo, S., Wells, G. A., Mesana, T. G., & Ruel, M. (2010) · Circulation · doi:10.1161/circulationaha.110.978007 · Cited by 223
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
Lip, G. Y. H., Andreotti, F., Fauchier, L., Huber, K., Hylek, E. M., Knight, E., Lane, D. A., Levi, M. M., Marín, F. R., Palareti, G., et al. (2011) · EP Europace · doi:10.1093/europace/eur126 · Cited by 224
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women
Lansky, A. J., Hochman, J. S., Ward, P. A., Mintz, G. S., Fabunmi, R. P., Berger, P. B., New, G., Grines, C. L., Pietras, C. G., Kern, M. J., et al. (2005) · Circulation · doi:10.1161/01.cir.0000155337.50423.c9 · Cited by 220
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J. A., Rockhold, F. W., Plotnikov, A. N., Mundl, H., Strony, J. T., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30751-1 · Cited by 227
Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome
Rassen, J. A., Choudhry, N. K., Avorn, J., & Schneeweiß, S. (2009) · Circulation · doi:10.1161/circulationaha.109.873497 · Cited by 218
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
Erlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.068 · Cited by 215
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J., Fitzgerald, D. J., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 233

Authors: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Affiliations: Hamilton General Hospital (CA)
Corresponding author: The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-08-16
Volume: 345
Issue: 7
Pages: 494-502
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa010746
OpenAlex: W1553345686
Cited by: 6,470
References: 16
Citations by year: 2026: 63 · 2025: 99 · 2024: 77 · 2023: 110 · 2022: 121 · 2021: 163 · 2020: 168 · 2019: 202 · 2018: 216 · 2017: 229 · 2016: 265 · 2015: 325 · 2014: 319 · 2013: 397 · 2012: 395
FWCI: 178.22
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: clopidogrel, aspirin, antiplatelet therapy, major bleeding, refractory ischemia, cardiovascular mortality, myocardial infarction, stroke, heart failure, revascularization
MeSH terms: Clopidogrel, Acute Disease, Aged, Aspirin, Cardiovascular Diseases, Drug Therapy, Combination, Electrocardiography, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Ticlopidine, Myocardial Ischemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks